Home   >  
Cell Cycle/DNA Damage
DNA Alkylator/Crosslinker

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

DNA Alkylator/Crosslinker

Chemical Structure Cat. No. Product Name CAS No.
CEP-40125 Chemical Structure
BCP30791 CEP-40125 1456608-94-8
CEP-40125, also known as RXDX-107, is a DNA alkylating drug potentially for the treatment of advanced solid tumours.
Calicheamicin Chemical Structure
BCP30641 Calicheamicin 108212-75-5
Calicheamicin is a cytotoxic agent that causes double-strand DNA breaks.
Ifosfamide Chemical Structure
BCP06596 Ifosfamide 3778-73-2
Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors.
Nimustine hydrochloride Chemical Structure
BCP11668 Nimustine hydrochloride 55661-38-6
Nimustine hydrochloride is a DNA alkylator and cross-linker. Anticancer agent used to treat malignant glioma. Cardiovascular teratogenicity was studied in rat fetuses.
Carmustine Chemical Structure
BCP27690 Carmustine 154-93-8
Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.
Ethyleneimine Chemical Structure
BCP29842 Ethyleneimine 151-56-4
Ethyleneimine is a monofunctional alkylating agent with potential antineoplastic activity.
BN-2629 Chemical Structure
BCP20924 BN-2629 232931-57-6
BN-2629 is a DNA-intercalating agent potentially for the treatment of ovarian cancer and leukemia.
SPDP Chemical Structure
BCP21722 SPDP 68181-17-9
SPDP is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls.
Disuccinimidyl suberate Chemical Structure
BCP29489 Disuccinimidyl suberate 68528-80-3
DSS crosslinker, or Disuccinimidyl suberate, is a homobifunctional crosslinker that is cell membrane permeable.
Satraplatin Chemical Structure
BCP14387 Satraplatin 129580-63-8
Satraplatin(BMS182751; BMY45594; JM216) is a platinum-based antineoplastic agent that is under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy
123下一页末页共 37 条记录 1 / 4 页